A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician's Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent
MD Anderson Study Status
rigosertib, Any approved or standard-of-care therapy, best supportive care (BSC)
The study's primary objective [in a population of patients with MDS after failure of treatment with azacitidine (AZA) or decitabine (DAC)], is to compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Myelodysplastic Syndrome, MDS, Refractory Anemia With Excess Blasts, RAEB
For general questions about clinical trials:
Help us #endcancer
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.